L8 Sturgill Cancer Immunotherapy and Tox

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/80

encourage image

There's no tags or description

Looks like no tags are added yet.

81 Terms

1
New cards

Cancer immunosurveillance is the normal ongoing function of a health immune system. SEQ cancer immunosurveillance.

  1. tumor cell elimination

  2. equilibrium

  3. tumor escape


2
New cards
  1. MP/DC activation by DAMPs via TLRs

  2. DC activation of CD4 helper T cells and CD8 cytotoxic T cells (CTLs) in draining lymph node

  3. Tumor destruction by CTLs (MHC-I/TAA)


tumor cell elimination

3
New cards
  1. where resistance develops

  2. ongoing tumor destruction by CTLs

  3. persistent tolerogenic antigen


equilibrium

4
New cards
  1. decreased MHC-expression

  2. appearance of inhibitory cytokines and checkpoint ligands

  3. appearance of inhibitory immune cells (MDSCs, Tr


tumor escape

5
New cards

What are checkpoint ligands?

when T cell binds and turns off; transform to Treg → anti-inflammation

6
New cards

What type of cells are the major antigen presenting cell to helper T cells and is only activated by APC?

dendritic cells

7
New cards

What happens when dendritic cells mature and migrate to the nearest lymphnode?

increased expression of MHC I/II and B7

8
New cards

dendritic have both MHC I and MHC II antigen processing pathways. CC them. This prevent inappropriate activation of T cells (which leads to cytokine syndrome)

MHC I: expressed by tumor cells; only CTL

  • only CD8 T cells and NK cells can bind

MHC II: only helper cells

  • Only CD4 T cells can bind

  • Only APCs express MHC II


9
New cards

What are the 3 signals required for CD4 helper T cell activation and polarization?

  1. antigen specifc: TCR (T cell) + MHC II (hold TAA) on DC

  2. co-stimulatory: CD28 (T cell) + B7 on DC

  3. polarizing: y-IFN and IL-12 promote Th-1 polarization; IL10 promotes Th-2 polarization


10
New cards

Activated Th-1 cells provide the third activating signal for

CD8 cytotoxic T cells (CTLs)

11
New cards

SLIDE 5

12
New cards

CTLs use lytic and non lytic mechanisms to destroy what?

destroy target cells expressing TAA bound to MHC I

13
New cards

non-lytic (not bolded)

secretion of y-IFN, TNF-a, IL-17 CCL5 (multiple inflammatory and regulatory effects)

14
New cards

lytic (not bolded)

  • cytotoxic enzymes (granzyme B, perforin

  • death receptors (promote apoptosis

  • binding of FasL (CTL) to Fas (tumor cel)

  • binding of TNFa to TRAIL (TNF-related apoptosis inducing ligand) on tumor cell


15
New cards

What are the FDA approved cancer immunotherapies?

  1. ICI

  2. adoptive T cell therapies: CAR-T cells, TCR-T cells, TILs

  3. Preventative and therapeutic cancer vaccines

  4. mAbs

  5. Oncolytic virus thearpy

  6. bispecific antibodies: blinatumomab

  7. Toll-like receptor agonists

  8. modulation of tumor microenvironment (TME)


16
New cards

Which cancer immunotherapy is associated with CRD and ICANs?

most common w CAR-T cells, rare with ICIs

  • also: TCR-T cells and bispecific antibodies


17
New cards

which cancer immunotherapy is associated with immune related adverse effects (irAEs)?

ICIs

18
New cards

ICI block inhibitory receptors on what? inhibitory receptors are only expressed by what?

T cells: PD-1, LAG-3, CTLA-4

Tumor cells: PD-L1

  • expressed by TAA-activated T cells (enhanced by chronic antigen exposure “tolerogenic”)


19
New cards

PD-1 is expressed by all activated T cells, Tregs, activated B cells, and activated NK cells. CC normal activity vs Anti-PD1 mAb activity

  1. NORMAL: PD-1 binds to PD-L1 on tumor cells: CTL activity inhibited; Treg activity enhanced

  2. BLOCK PD-L1 or PD-1: T cell killing of tumor cell


20
New cards

FDA approved PD-1 blockers


21
New cards

PD-L1 is normally expressed by T-cells, B cells, MPs, DCs, neutrophils, and various tissues, including tumor cells. How do Anti-PD-L1 mAbs downregulate cancer?

binding fo PD-1 inhibts T cell activation

22
New cards

What are the FDA approved PD-L1 blockers

atezolizumab, duravlumab, avelumab, cosibelimab-ipdl

23
New cards

CTLA is expressed by activated CD8 T cells (CTLs) which competes with CD28 for binding to B7 on DC. What does this promote?

development and inhibitory activity of regulatory T cells (Tregs)

24
New cards

What are the FDA approved CTLA-4 blockers?

ipililumab, tremelimumab

25
New cards

How does CTLA-4 inhibition work?

CTLA-4/B7 binding inhibits T cell activation, CTLA04 block alllows T cell killing of tumor cell

26
New cards

LAG-3 is expressed by activated CD4 and CD8 T cells and is constitutively expressed by Tregs (always). What does it bind to?

binds to stable MC II on DC and prevents CD4 T cell activation

27
New cards

What are the FDA approved LAG-3 blockers?

nivolumab (anti-PD-1) and relatlimab-rmbw (anti-LAG-3); aka Opdualag

28
New cards

How do LAG-3 blockers work?

bind to LAG-3 receptor on T cell; prevents binding to stable MHC II, allow CD4 t cell activation and cause an antitumor response

29
New cards

What are the most common immune related AEs associated with ICIs? How should you monitor patients on ICIs?

enterocolitis, hepatitis, dermatitis, (toxic epidermal necrolysis), neuropathy, and endocrinopathy

  • assess for S/S, eval LFTs, ACTH level, and thyroid function test at baseline before each dose


30
New cards

If a patient on ICIs experienee irAEs, what should you do?

if this happens permanently d/c therapy and start high dose corticosteroid therapy

  • may also occur weeks-mo after d/c


31
New cards

Which ICI is most likely to cause immune related AEs?

ipilimumab and severe AEs

32
New cards

Dermatology irAEs are associated with better overall and progression free survival. What are the more common ones?

  1. maculopapular rash, itching, vitiligo (melanoma only)

  2. DRESS and SJS/TEN more common with combo CTLA/PD-1 blockers


33
New cards

if pt on ICI exerpeinces grade 1 dermatologic irAEs, what should you give them?

topical corticosteroid, oral anthistamine

34
New cards

if pt on ICI exerpeinces grade 2 dermatologic irAEs, what should you give them?

systemic corticosteroid

35
New cards

if pt on ICI exerpeinces grade >=3 dermatologic irAEs, what should you give them?

hold therapy, derm consult; systemic corticosteroid 1-2mg/kg/day

36
New cards

T/F Colitis has a higher overall incidence and incdience of Grade 3-4 colitis with combination CTLA/PD-1 blockers.

true

37
New cards

If patient on ICI has colitis >= grade 2 irAE, what should you do?

hold therapy, GI consult; systemic corticosteroid 1-2mg/kg/d; rule out infection

  • consider infliximab or vedolizumab if no result after 3-5 days


38
New cards

T/F hepatitis irAE from ICI is dose dependent with ipilimumab and is more common with combination with CTLA/PD-1 blockers

true

39
New cards

At week 6-14 of ICI therapy, how does hepatitis irAE present itself?

usually asymptomatic increase in LFTs, rarely acute liver failure

40
New cards

If pt on ICI has Grade 1 hepatitis irAE, what should you give them?

continue therapy with close monitoring of LFTs

41
New cards

If pt on ICI has Grade 2 hepatitis irAE, what should you give them?

hold therapy; systemic corticosteroid

42
New cards

If pt on ICI has Grade 3 hepatitis irAE, what should you give them?

hold therapy; hepatology consult

  • systemic corticosteroid 1-2mg/kg/d

  • consider mycophenolate mofetil if no result after 3-5 days (NO INFLIXIMAB CUZ HEPATOTOX RISK)


43
New cards

When are thyroid irAEs in ICI therapy more common? When is onset usually?

ICI in combo with CTLA/PD-1 blockers; more common with PD-1 blockers than ipilimumab

  • hypothyroidism > hyperthyoidism (onset 4wks of therapy)


44
New cards

If patient on ICI has asymptomatic thyroid irAEs, what should you give them?

levothyroxine if TSH >10 mIU/L; rule out adrenal insufficiency

45
New cards

If patient on ICI has symptomatic thyroid irAEs, what should you give them?

levothyroxine; rule out adrenal insufficiency

46
New cards

If patient on ICI has hyperthyroidism irAEs, what should you give them?

endocrine consult; propanolol for symptom control

47
New cards

When are pituitary irAEs from ICI most common?

can result from thyroid, adrenal, or gonadal axis dysfunction

most common w combo CTLA/PD-1 blockers; dose dependent with ipilimumab

48
New cards

If patient gains adrenal insufficiency from ICI pituitary irARs, what should you give them

typically permanent; lifelong hormonal replacement therapy (levothyroxine and steroid replacement)

49
New cards

When treating hypophysitis/adrenal insufficiency irAEs from ICI treatment, how should you initiate treatment? how should you avoid/treat adrenal crisis?

  • begin steroid replacement prior to levothyroxine to avoid adrenal crisis

  • corticosteroid 1-2mg/kg/d to treat adrenal crisis


50
New cards

Chimeric antigen receptor (CAR) T cells do not require what

do not require antigen processing and presentation by APCs

51
New cards

SEQ how CAR T cells are engineered

  1. remove blood from pt to get T cells

  2. make CAR t cells in lab

  3. grow CAR t cells and infuse into pt

  4. CAR t cells bind to cancer cells and kill them


52
New cards

What are the common ADE of CAR T cells? (20%)

  1. Cytokine release syndrome(CRS)

  2. encephalopathy

  3. hypogammaglobulinemia, infection, fever, cough

  4. dec appetite, HA, n/v/d/f

  5. bleeding eps and tachycardia


53
New cards

What are the problems with CAR T cells?

  1. poor penetration of solid tumors

  2. T cell exhaustion (apoptosis) mediated by tumor microenvironment

  3. TAA loss (tumor stops expressing CD19) and increased heterogeneity


54
New cards

What are the BBW of CAR-T cells?

  1. cytokine release syndrome

  2. neurologic toxicities


55
New cards

Describe cytokine release syndrome (CRS) due to CAR T cell toxicity. What causes it, onset, symptoms, treatment

  1. due to CAR T cell activation and release of inflamm cytokines IL-6 and IFNy

  2. during first 2 wks; flu-like symptoms to severe sepsis-like syndrome requiring ICU management (HoT, organ dys, coag, pancyto, infection)

  3. treat w corticosteroids and toxilizumab


56
New cards

Describe neurologic toxicities due to CAR T cell toxicity. What causes it, onset, symptoms, treatment

  1. 25-50% of pts usually accomp w CRS

  2. mild confusion and somnelence to encephalopathy syndome (seiz, focal def, cerebral edema (fatal), coma)

  3. treatment: corticosteroids only w supportive care


57
New cards


Anti-CD19 CAR T cells

58
New cards

What are the Anti-BCMA CAR T cells?

idecabtagene vicleucel and ciltacabtagene autoleucel

59
New cards

What is Cytokine release syndrome?

run-away immunse system activation resulting from any immune therapy involving target cell engagement and activation of endogenous or infused T cells that begins 1-14 days after drug admin

60
New cards

pt recently began CAR T cell therapy (within 1-14 days), and is experiencing cold like symptoms (fever, malaise, myalgias, fatigue, rash).

  • Later on, they experience a capillary leak (hypoxia, peripheral/pulmonary edema), HoT, and multiorgan dysfunction/failure.

  • What ADE are they experiencing?


cytokine release syndrome (CRS)

61
New cards

What are the risk factors of CRS from CAR T cell therapy?

ALL, high tumor burden, higher CAR T cell dose

62
New cards

LOOK AT THIS SLIDE: CRS symptoms


63
New cards

Pt has

  • Fever: Temperature ≥38°C

  • Hypotension: None (no hypotension symptoms)

  • Hypoxia: None (no hypoxia symptoms / "good O2 stats")

What CRS grade is this and what should you treat them with


Grade 1;

  • supportive care: Fluids, antipyretics, analgesics

  • consider

    • metoprolol to block IL-6 synthesis

    • leveitracetam for seizure prophylaxis


64
New cards

pt has a temperature ≥38°C plus not requiring vasopressors (for HoT) and/or requiring low-flow nasal cannula or blow-by (for hypoxia)

  • What CRS grade is this and what should you treat them with


Grade 2

  • same supportive care as grade 1

  • begin levetiracetam (Keppra)

  • Toclizumab max 4 doses; (if refractory HoT)add dexmethasone 10mg IV q 12hr

  • if no improvement within 24 hr escalate to grade 3 guidelines


65
New cards

Pt has

  • Fever: Temperature ≥38°C

  • Hypotension: Requiring a vasopressor

  • Hypoxia: Requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask

What CRS grade is this and what should you treat them with


Grade 3

  • same supportive care as grade 1

  • ECHO

  • Vasopressors as indicated

  • toclizumab + dexamethasone; if refractory, escalate to Grade 4 guidelines


66
New cards

If pt has

  • Fever: Temperature ≥38°C

  • Hypotension: Requiring multiple vasopressors

  • Hypoxia: Requiring positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation)

What CRS grade is this and what should you treat them with


Grade 4;

  • same supportive care as grade 1

  • add mechanical ventilation prn

  • Toclizumab + methylprednisolone 500mg IV q3hr 3 d then 250mg IV q12 hr for 2 days, then 125mg IV q12 for 2 days, then 60mg IV q12 hr until back to CRS grade 1


67
New cards

What are additional therapies with limited evidence for grade 4?


68
New cards

What is toclizumab?

humanized mAb that targets IL-6 receptor (receptor that drives CRS tox); 69% response rate, resolution within 14 days, no more than 2 doses

  • fever usually resolves within hours of admin


69
New cards

What is the BBW of toclizumab?

serious infections leading to hospitalization or death (TB, bacterial, invasive fungal, viral, other opportunistic infections)

  • DO NOT ADMIN IN PT WITH ACTIVE INFECTION


70
New cards

Recommended dose for toclizumab? (dont think we need to mem)


71
New cards

pt recently started receiving CAR-T cell therapy. They started experiencing difficulty speaking or naming objects (expressive aphasia) but over a few hours-days it has progressed to global asphasia (awake but unable to communicate or follow commands). If untreated it can lead to obtundation, coma, seizures, cerebral edema. What does the patient have?


  • immune effector cell-associcate neurotoxicity syndrome (ICANS)

  • CAR T-cell related encephalopathy syndrome (CRES)


72
New cards

If ICANS is associated with CRS, what should you consider?

toclizumab

73
New cards

If patient has Grade 1 ICANs, how should you treat the patient?

  1. aspiration precautions; IV hydration

  2. avoid CNS depressants

  3. seizure prophylaxis: Levetiracetam 750mg q12h

  4. agitation: Lorazepam -.25-0.5mg IV q8h or Haloperidol 0.5mg IV q6h

  5. Neuro consult

  6. fundoscopic exam to rule out papilledema

  7. daily EEG until symptoms resolve


74
New cards

If pt has Grade 2 ICANS, and if not assoc w CRS or refractory to toclizumab if CRS Present, how should you treat them?

Dexamethasone 10mg IV q6h OR Methylprednisolone 1mg/kg q12


75
New cards

If pt has Grade 2 ICANS, and is associate with grade >=2 CRS, how should you treat them?

ICU transfer

76
New cards

If pt has Grade 3 ICANS how should you treat them?

  1. transfer to CU

  2. continue corticosteroids(dexamethasone or methylprednisolone from grade 2)

  3. repeat CT or MRI every 2-3 days for persistent grade >=ICANS


77
New cards

If pt has Grade 4 ICANS how should you treat them?

  1. ICU monitoring; consider mechanical ventilation for airway protection

  2. continue corticosteroids (dexamethasone or methylprednisolone from grade 2)


78
New cards

How can you minimize the risk of CRS/ICANS with CAR T cell therapy?

  1. SQ admin: atezolizumab

    1. gradual use of escalating SQ administration over several days

    2. gradual introduction to desensitive patient’s immune system to therapy

  2. third, fourth, fifth gen CAR-T cells


79
New cards

Describe third gen CAR-T cells

2 costimulatory molecules:

  • CD28: rapid activation/tumor killing but faster T-cell exhaust

  • 4-1BB: slow cell prolif, longer duration of fx, promote memory T cells, long term pt survival


80
New cards

Describe fourth gen CAR-T cells

“T cells redirected for universal cytokine mediated killing” (TRUCKs)

  • secrete cytokines (IL) or anti-IL 6/anti-TNDa scFvs that modify tumor microenvironment to enhance tumor kill


81
New cards

Describe fifth gen CAR-T cells

IL-2 receptor B signaling domain that enhances IC cytokine signaling (STAT3/5 pathway)

  • most resistant to T cell exhausation

  • lower risk CRS/ICANS